Skip to content
OpenCapital
Get started

Teladoc Health TDOC Deferred Device Cost And Other Noncurrent

Other financials

Income statement

See full
Revenue$613.8M-2.5%
Gross profit$416.3M-3.8%
Operating income-$61.8M+48.8%
Net income-$63.8M+31.4%
EPS (diluted)-$0.36+32.1%

Balance sheet

See full
Cash & equivalents$750.7M-37.1%
Total debt$42.2M-92.9%
Total equity$1.3B-6.4%
Total assets$2.8B-18.5%

Cash flow

See full
Operating cash flow$9.5M-40.2%
CapEx$1.7M-39.1%
Free cash flow$7.9M-40.5%

Valuation

See full
Market cap$1.41B+16.5%
Enterprise value$701.31M+14.7%
P/S0.6×+0.1×

Profitability

See full
Gross margin69.3%-1.2pp
Operating margin-8.1%-3.6pp
Net margin-6.8%-3.1pp
FCF margin11.1%-0.2pp

Returns & leverage

See full
Return on equity-12.4%-5.4pp
Debt / equity0×-0.4×
Current ratio2.8×+1.1×

Where this comes from

Reported directly by Teladoc Health in its filing.

Tagged under the XBRL concept tdoc:DeferredDeviceCostAndOtherNoncurrent.

The official record: Teladoc Health’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Teladoc Health's deferred device cost and other noncurrent.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Teladoc Health's deferred device cost and other noncurrent?
Teladoc Health (TDOC) reported deferred device cost and other noncurrent of $15.56M in Q1 2026.
How has Teladoc Health's deferred device cost and other noncurrent changed year-over-year?
Teladoc Health's deferred device cost and other noncurrent decreased by 10.1% year-over-year, from $17.31M to $15.56M.
What is the long-term trend for Teladoc Health's deferred device cost and other noncurrent?
Over 3 years (2022 to 2025), Teladoc Health's deferred device cost and other noncurrent has grown at a 18.9% compound annual growth rate (CAGR), from $8.4M to $14.13M.